CD22 and non-Hodgkin lymphoma: In a phase I/II study, fractionated anti-CD22 RIT using 90Y-epratuzumab tetraxetan showed a high rate of durable CR and ORR in 41% to 73% of the patients with relapsed/refractory NHL [25].